401484
IKK-2 Inhibitor IV
InSolution, ≥95%
Synonym(s):
InSolution IKK-2 Inhibitor IV
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
Assay
≥95% (HPLC)
form
liquid
potency
18 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
color
clear pale yellow
shipped in
wet ice
storage temp.
2-8°C
General description
IKK-2 Inhibitor IV (Cat. No. 401481) supplied in DMSO. A cell-permeable and potent inhibitor of IKK-2 (IC50 = 18 nM) that exhibits selectivity over IKK-1, JNK, and p38 MAPK. Inhibits TNF-α production in human monocytes (IC50 in the range of 0.15-2.5 µM) and blocks IL-8 and IL-6 production by synovial fibroblasts (IC50 = 100 nM). Shown to reduce paw oedema in rat arthritis model (~100% inhibition at a dose of 30 mg/kg).
Biochem/physiol Actions
Cell permeable: yes
Product competes with ATP.
Reversible: yes
Packaging
Packaged under inert gas
Warning
Toxicity: Irritant (B)
Physical form
A 10 mM (500 µg/179 µl) solution of IKK-2 Inhibitor IV (Cat. No. 401481) in DMSO.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
188.6 °F - closed cup - (Dimethylsulfoxide)
Flash Point(C)
87 °C - closed cup - (Dimethylsulfoxide)
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells.
Frontiers in oncology, 12, 762820-762820 (2022-04-05)
Epithelial ovarian cancer (EOC) is a global health burden and remains the fifth leading cause of cancer related death in women worldwide with the poorest five-year survival rate of the gynecological malignancies. EOC recurrence is considered to be driven by
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service